Cipla’s withdrawal of antibiotic marketing application latest sign of AMR market failure

Cipla has withdrawn its application for EMA approval of Zemdri, an antibiotic it acquired in a fire sale from Achaogen after the biotech declared bankruptcy. Cipla stated that the costs of meeting pre- and post-approval requirements, including addressing EMA concerns

Read the full 407 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE